Iron or vitamin B12 deficiency in anemic cancer patients prior to erythropoiesis-stimulating agent therapy

Community Oncology

Volumn 4, Issue 2, 2007, Pages 93-101

  Henry, David H ^a   Dahl, Naomi V ^b,c,d  

^a PENNSYLVANIA HOSPITAL   (United States)

^b Watson Laboratories Inc   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d Watson Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; CYANOCOBALAMIN; FERRIC GLUCONATE; FERRITIN; FOLIC ACID; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYANOCOBALAMIN DEFICIENCY; DRUG RESPONSE; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON THERAPY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE HEMOGLOBIN CONTENT; TRANSFERRIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 34047155244     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1548-5315(11)70057-2     Document Type: Article

References (42)

1. Henry DH. Supplemental iron: a key to optimizing the response of cancer-related anemia to rHuEPO? Oncologist 1998;3:275-278.
2. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
3. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
4. Lee GR. Iron deficiency and iron deficiency anemia. In: Lee GR, Bithell TC, Foerster J, et al, eds. Wintrobe's Clinical Hematology. Philadelphia, Pa: Lea & Febiger; 1993:808-839.
5. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhom LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
6. Glaspy J, Vadhan-Raj S, Patel R, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 2006;24:2290-2297.
7. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B; Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
8. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303-2320.
9. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
10. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-2617.
11. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307.
12. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR; Ferrlecit Cancer Study Group. Intravenous ferric gluconate significandy improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. The Oncologist. In press.
13. Vandebroek A, Gaede B, Altintas S, et al. A randomized open-label study of darbepoetin alfa administered every 3 weeks with or without parenteral iron in anemic subjects with nonmyeloid malignancies receiving chemotherapy. J Clin Oncol 2006;24(18S):8612.
14. Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000;11:530-538.
15. Fishbane S, Lynn RI. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin Nephrol 1995;44:238-240.
16. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995;26:41-46.
17. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-1699.
18. Warady BA, Kausz A, Lerner G, et al. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 2004;19:655-661.
19. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000;96:823-833.
20. Cancer and treatment related anemia. NCCN Clinical practice guidelines in oncology. National Comprehensive Cancer Network. Version 2.2006. Available at: www.nccn.org/professionals/physician_gls/PDF/anemia.pdf. Accessed August 17, 2006.
21. Levey AS. Clinical practice: nondiabetic kidney disease. N Engl J Med 2002;347:1505-1511.
22. Procrit (epoetin alfa) [prescribing information]. Raritan, NJ: Ortho Biotech Products, L.P.; 2006.
23. Aranesp (darbepoetin alfa) [prescribing information]. Thousand Oaks, CA: Amgen Inc.; 2006.
24. Baynes RD. Assessment of iron status. Clin Biochem 1996;29:209-215.
25. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
26. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002;48:1066-1076.
27. Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem 2003;49:1573-1578.
28. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102:783-788.
29. Cavill I. Iron status as measured by serum ferritin: the marker and its limitations. Am J Kidney Dis 1999;34(4 suppl 2):S12-S17.
30. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004;19:141-149.
31. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998;79:299-305.
32. Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 2006;19:161-167.
33. Feelders RA, Vreugdenhil G, Eggermont AM, Kuiper-Kramer PA, van Eijk HG, Swaak AJ. Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest 1998;28:520-527.
34. Brugnara C, Chambers LA, Malynn E, Goldberg MA, Kruskall MS. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. Blood 1993;81:956-964.
35. Macdougall IC, Cavill I, Hulme B, et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. BMJ 1992;304:225-226.
36. Brugnara C, Zurakowski D, DiCanzio J, Boyd T, Platt O. Reticulocyte hemoglobin content to diagnose iron deficiency in children. JAMA 1999;281:2225-2230.
37. Cullen P, Soffker J, Hopfl M, et al. Hypochromic red cells and reticulocyte haemoglobin content as markers of iron-deficient erythropoiesis in patients undergoing chronic haemodialysis. Nephrol Dial Transplant 1999;14:659-665.
38. Fishbane S, Galgano C, Langley RC Jr, Canfield W, Maesaka JK. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997;52:217-222.
39. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001;60:2406-2411.
40. Groom AC, Song SH, Campling B. Clearance of red blood cells from the vascular bed of skeletal muscle with particular reference to reticulocytes. Microvasc Res 1973;6:51-62.
41. Mitsuiki K, Harada A, Miyata Y. Assessment of iron deficiency in chronic hemodialysis patients: investigation of cutoff values for reticulocyte hemoglobin content. Clin Exp Nephrol 2003;7:52-57.
42. Mast AE, Blinder MA, Lu Q, Flax S, Dietzen DJ. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood 2002;99:1489-1491.